Study: ICD patients can exercise without errant shock risks; Adagio Medical raises $2.5M;

@FierceMedDev: Cardiac Science sells off diagnostic biz, focuses on defibrillators. News | Follow @FierceMedDev

@MarkHFierce: Folks have figured out a way to goose Dx tech that could enable personalized prostate cancer treatments. Release | Follow @MarkHFierce

 @DamianFierce: Now, per Reuters, Thermo Fisher is in the lead with a $12B bid on Life Tech. More | Follow @DamianFierce

> Acclarent, a division of Johnson & Johnson ($JNJ), got served with an FDA warning letter for changing a device's training materials without notifying the agency. Letter

> GnuBIO has launched beta versions of its desktop DNA sequencing system, which the company says is cheaper and faster than its competitors. Article

> Maine's NorDx is expanding its diagnostic capabilities with hematology analysis technology acquired from Japan's Sysmex. Release

> According to a new study, excercise doesn't raise the risk of errant shocks in heart failure patients implanted with ICDs. Story

> Sandia National Laboratories developed a diagnostic device--a lab on a disk--designed to screen for anthrax, ricin or other bioterror agents. Story

> T2 Biosystems has secured another patent to cover T2Candida, its blood diagnostic for the sepsis-causing infection. Item

> California startup Adagio Medical raised $2.5 million toward developing novel devices to treat cardiovascular disease. Story

Biotech News

@FierceBiotech: Elan closes $3.25B Tysabri deal and preps for biotech deal spree. News | Follow @FierceBiotech

@JohnCFierce: AstraZeneca's latest biotech deal offers more early-stage research work. Years away from PhIII, where it needs help. More | Follow @JohnCFierce.

@RyanMFierce: Pfizer made an another early-stage deal with a Cambridge, MA biotech. This one with Gates-backed Tetragenics. Release | Follow @RyanMFierce

> AstraZeneca gambles on cardio therapy in AlphaCore buyout. Report

> Resurgent Pfizer partners with Bind on new nanotech drug effort. News

> Biotech gamblers crowd high-stakes game for Sarepta. More

Pharma News

@FiercePharma: Tough German pricing authority backs Pfizer/BMS drug Eliquis as stroke preventive; 'significant' benefit. Report | Follow @FiercePharma

@EricPFierce: Lilly is installing some new technology in its US insulin cartridge plant, to pump up output. Article | Follow @EricPFierce

> Pfizer, Novartis eye bids for Brazil's Ache in deal worth $5B. Story

> South Africa's Adcock Ingram rebuffs buyout by conglomerate. More

> Valeant fires back at Merz with $415M-plus Obagi bid. News

Biomarkers News

 @EmilyMFierce: New prostate cancer predictors revealed. Report | Follow @EmilyMFierce

> CV biomarker study finds evidence of bias, exaggeration in the field. Story

> French researchers cast doubt on chemo biomarker's viability. Item

> Biomarkers predict risk of diabetes-related kidney trouble. Article

> U.K. team concocts rapid approach for colorectal cancer biomarker detection. More

Drug Delivery News

@MichaelGFierce: Biogen Idec's new oral MS drug Tecfidera has an unknown mechanism of action, the company says. More | Follow @MichaelGFierce

> Cholesterol 'rafts' enable cancer-killing delivery of DNA, RNA. Report

> Analysts expect nanotech drug delivery boom despite safety concerns. Story

> Pozen seeks FDA approval for layered aspirin cardiovascular treatment. Item

> FDA rejects A.P. Pharma's delayed-onset chemo drug. More

> Entrega, other startups make strides in needle-free delivery. Article

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.